0
Skip to Content
Context Therapeutics
Who We Are
Our Technology
Pipeline
CTIM-76
CT-95
CT-202
Patients
Careers
Investors & News
Context Therapeutics
Who We Are
Our Technology
Pipeline
CTIM-76
CT-95
CT-202
Patients
Careers
Investors & News
Who We Are
Folder: Our Science
Back
Our Technology
Pipeline
CTIM-76
CT-95
CT-202
Patients
Careers
Investors & News

News

Sigma1 Targeting to Suppress Aberrant Androgen Receptor Signaling in Prostate Cancer
Publications Fiona O'Leary Sloan 4/11/17 Publications Fiona O'Leary Sloan 4/11/17

Sigma1 Targeting to Suppress Aberrant Androgen Receptor Signaling in Prostate Cancer

Thomas, JD, Oyer, HM, Kim, FJ, et al. Cancer Research.

Read More
Newer Posts

About Us
Leadership
Partnering
Contact Us

Our Technology
Pipeline
CTIM-76
CT-95
CT-202

Patients
Clinical Trials
Investigator Led Trials
Access Policy

Investors & Media
News
Publications

Careers
Open Positions

Privacy Policy          Terms of Use

© Context Therapeutics Inc. 2026  |  All Rights Reserved